Trevena (TRVN) Given Daily Coverage Optimism Rating of 0.08
Media coverage about Trevena (NASDAQ:TRVN) has trended somewhat positive recently, Accern reports. Accern identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Trevena earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.344329465743 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the media stories that may have effected Accern’s rankings:
- Trevena, Inc. (NASDAQ:TRVN) – Hot Stock That Must Be in Your Portfolio – Nasdaq Journal (press release) (nasdaqjournal.com)
- Trading summary of Unusual Activity – Trevena, Inc. (TRVN) – Wall Street Morning (wallstreetmorning.com)
- Stocks Trend Prediction: Trevena, Inc. (TRVN), TD Ameritrade Holding Corporation (AMTD) – Market Movers (financialqz.com)
- Trevena, Inc. (TRVN) Jumps: Stock Rises 11.7% – Nasdaq (nasdaq.com)
- Trevena (TRVN) Stock: Soaring On FDA News (cnafinance.com)
TRVN has been the subject of a number of recent analyst reports. HC Wainwright cut their price target on shares of Trevena from $8.00 to $7.00 and set a “buy” rating for the company in a report on Thursday, October 12th. Zacks Investment Research downgraded shares of Trevena from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. Barclays downgraded shares of Trevena from an “overweight” rating to an “equal weight” rating and cut their price target for the stock from $15.00 to $2.50 in a report on Monday, October 16th. Needham & Company LLC cut their price target on shares of Trevena from $9.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, November 8th. Finally, Oppenheimer set a $5.00 price target on shares of Trevena and gave the stock a “buy” rating in a report on Thursday, October 12th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $8.09.
Trevena (TRVN) opened at $1.76 on Tuesday. The company has a market cap of $105.07, a P/E ratio of -1.07 and a beta of -0.58. The company has a debt-to-equity ratio of 0.38, a current ratio of 4.92 and a quick ratio of 4.92. Trevena has a 52 week low of $1.35 and a 52 week high of $8.00.
Trevena (NASDAQ:TRVN) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.33) by $0.06. During the same quarter in the prior year, the company posted ($0.57) EPS. equities analysts expect that Trevena will post -1.23 earnings per share for the current year.
Trevena Company Profile
Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.